Nutrition Consensus

Evidence sentiment publication

[VINO] Beverages

Red Wine

Last updated Jul 18, 2026 · Refresh target: weekly

Is red wine good for you today?

Genuinely contested. A large polyphenol/resveratrol and French-paradox literature keeps the ledger barely positive, but high-quality modern evidence — the GBD 'no safe level' analysis, alcohol-cancer dose-response, and Mendelian-randomization studies that debunk the J-curve — pulls hard the other way. Net: mixed — barely off zero, low confidence, very high controversy.

Additional analyst color: The French paradox's last stand. The Mendelian-randomization desk is bearish.

Current score

-2

Sentiment

Mixed

Confidence

51 / 100

Controversy

46 / 100

Very contested

Evidence items

159

30D0
90D-6
1Y-8

The beverage desk is split. The bull case is decades of resveratrol mechanism and observational cardioprotection studies; the bear case is that those were confounded by 'sick quitters', alcohol is a Group 1 carcinogen, and causal-inference work finds no safe level. The score sits near zero because both books are heavy.

Analyst noteConfidence is low: the favorable and unfavorable evidence have comparable weight and point in opposite directions, so the model has plenty of signal but little agreement.

Last meaningful move

Jun 2026

Score move

-6

points

Driven by

Alcohol Intake and Health Study: No Protective Effect at Low Levels, With Mortality Increasing to 1 in 25 at 14 Drinks Per Week

Journal of Studies on Alcohol and Drugs · Jun 9, 2026 · Strong negative · index impact -45

This study carried one of the largest negative public impacts added to the ledger around the move.

View study ->

Evidence sentiment index

Historical price of the red wine thesis

Start
End
-100+10+20Zero line: mixed
Latest-2
SignalMixed
Confidence51 / 100

Axis fitted: -10 to +20. Index scale remains -100 to +100.

Latest studies

Evidence tape

Sorted by evidence availability date, newest first.

Did we miss a study?

Showing 3 of 159 studies after filter and sort.

large prospective cohort

Wine consumption, Mediterranean diet, and cardiovascular risk in two Spanish cohorts.

European heart journal · Jul 14, 2026Open study
Direction: NeutralIndex impact 0

PREDIMED (n=7,447) and SUN (n=23,133) Spanish cohorts: MedDiet adherence including wine tracked lower CVD (HR 0.55) and all-cause mortality (HR 0.67), but the wine-specific benefit was not robust - no risk reduction at 3+ glasses/day, analyses least vulnerable to abstainer bias were non-significant, wine interaction terms were non-significant, and no significant wine associations appeared in the SUN cohort.

Details and limitations

Limitations: Review full paper for confounding, population characteristics, endpoint definitions, and study design before publishing.

Evidence weight 22 / 100pubmedjournal-articlemulticenter-studydoi:10.1093/eurheartj/ehaf1081pmid:41667089

large prospective cohort

Associations between beer, wine, and spirits consumption and major mortality outcomes in 187,294 Norwegian men and women, with a focus on low-level wine intake.

Scandinavian journal of public health · Jul 3, 2026Open study
Direction: NeutralIndex impact 0

Norwegian cohort (n=187,294, 21-yr follow-up, 15,642 deaths): low wine intake (alone or with low beer/spirits) was associated with lower all-cause mortality (HR 0.84-0.90) versus non-drinkers, while 20+ glasses/14 days raised all-cause (HR 1.44) and alcohol-related mortality steeply. Non-drinker reference is subject to abstainer bias; the light-intake J-curve is not causally established.

Details and limitations

Limitations: Review full paper for confounding, population characteristics, endpoint definitions, and study design before publishing.

Evidence weight 20 / 100semanticscholarjournalarticlereviewdoi:10.1177/14034948261459749pmid:42396751

meta analysis

The effects of resveratrol on glycemic indices and lipid profile in patients with type 2 diabetes: an umbrella review and meta-analysis.

Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · Jun 10, 2026Open study
Direction: PositiveIndex impact +22

abstract suggests a favorable signal. BACKGROUND: Growing evidence supports the therapeutic role of nutraceuticals as complementary and alternative therapies in patients with type 2 diabetes mellitus (T2DM).

Details and limitations

Limitations: Review full paper for confounding, population characteristics, endpoint definitions, and study design before publishing.

Evidence weight 33 / 100pubmedjournal-articlesystematic-reviewdoi:10.1007/s40199-026-00609-xpmid:42268476

Showing 3 of 159 studies.